ALDER BIOPHARMACEUTICALS, INC.
11804 North Creek Parkway South
Bothell, WA 98011
January 5, 2015
VIA EMAILAND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Jeffrey P. Riedler |
| Matthew Jones |
| RE: | Alder BioPharmaceuticals, Inc. |
Registration Statement on Form S-1
File No. 333-201201
Ladies and Gentlemen:
Alder BioPharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on January 7, 2015, at 3:00 p.m., Eastern Time, or at such later time as the Registrant or its counsel may orally request via telephone call to the Staff of the Division of Corporate Finance of the Commission.
In connection with this request, the Registrant acknowledges that:
| • | should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
| • | the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| • | the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Very truly yours,
Alder BioPharmaceuticals, Inc.
/s/ Randall C. Schatzman
Randall C. Schatzman
President and Chief Executive Officer